References
- Stübgen J-P. Lymphoma-associated dysimmune polyneuropathies. J Neurol Sci. 2015;355(1–2):25–36.
- Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136(8):2563–2578.
- Viala K, Béhin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79(7):778–782.
- Mathey EK, Park SB, Hughes RAC, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973–985.
- Van den Bergh PYK, Hadden RDM, Bouche P, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356–363.
- Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973–976.
- Vallat JM, De Mascarel HA, Bordessoule D, et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies–13 cases. Brain J Neurol. 1995;118(5):1233–1245.
- Sah SP, Matutes E, Wotherspoon AC, et al. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. J Clin Pathol. 2003;56(2):129–132.
- Costopoulos M, Kim R, Choquet S, et al. Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Semin Hematol. 2018;55(4):179–181.
- Bourque PR, Warman Chardon J, Bryanton M, et al. Neurolymphomatosis of the brachial plexus and its branches: case series and literature review. Can J Neurol Sci. 2018;45(2):137–143.
- Sanvito L, Makowska A, Mahdi-Rogers M, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009;80(3):333–338.
- Garcia-Santibanez R, Zaidman CM, Sommerville RB, et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol. 2018;265(6):1402–1409.
- Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e149.
- Sala E, Robert-Varvat F, Paul S, et al. Acute neurological worsening after rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci. 2014;345(1–2):224–227.
- Ghobrial IM, Uslan DZ, Call TG, et al. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to waldenström macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77(4):329–330.
- Rossignol J, Michallet A-S, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia. 2011;25(3):473–478.